Important Message: Beware of Impersonation Scams

Fraudulent messages and advertisements are currently circulating on messaging platforms, including WhatsApp, impersonating Candriam’s brand and investment professionals. Please note that Candriam never offers investment recommendations or provides financial advice through social media channels or messaging platforms.

Sara Torrecilla - Senior Equity Analyst – Healthcare
About

Sara Torrecilla

Senior Equity Analyst – Healthcare

Sara Torrecilla has been with Candriam’s Healthcare team since 2020, where she serves as a Senior Equity Analyst. She is responsible for the analysis of biotechnology and pharmaceutical companies, contributing to the management of publicly listed healthcare equity strategies within the Global Thematic Equity platform. 

Prior to joining Candriam, Sara worked as an Investment Analyst for the healthcare fund of M Ventures, the corporate venture arm of Merck KGaA, in Amsterdam. Earlier in her career, she was a Biomedical Scientist conducting research in the field of liver cancer at Hospital Clinic (Barcelona) and the Icahn School of Medicine at Mount Sinai (New York). 

Sara holds a PhD in Medicine and Translational Research, awarded with cum laude distinction, and a Master of Science in Translational Medicine, both from the Universitat de Barcelona. 

Discover the latest articles by Sara Torrecilla

Linden Thomson, Sara Torrecilla, Healthcare

Biotechnology in 2026: innovation with selectivity

After a stronger 2025, biotechnology entered 2026 on firm footing. Innovation remains robust, valuations are still supportive and investor interest is improving. In a selective market, Candriam focuses on differentiated assets, commercial potential and disciplined portfolio construction.
Loading...

Find it fast

Get information faster with a single click

Get insights straight to your inbox